Incyte Announces 2021 Incyte Ingenuity Award Program Recipients, Recognizing Innovative Solutions for the GVHD Community

Memorial Sloan Kettering Cancer Center and the Aplastic Anemia and MDS International Foundation selected to receive the $100,000 and $35,000 awards, respectively.

WILMINGTON, Del. – October 29, 2021 – Incyte today announced that Memorial Sloan Kettering Cancer Center and the Aplastic Anemia and MDS International Foundation are the 2021 Incyte Ingenuity Award program recipients. This annual award program, which debuted in 2020, aims to support the U.S. graft-versus-host disease (GVHD) community by funding two novel initiatives that address challenges faced by GVHD patients, caregivers and healthcare providers. All Incyte Ingenuity Award applications were reviewed and evaluated by an independent judging panel, consisting of GVHD experts and advocates.

Memorial Sloan Kettering Cancer Center has been selected to receive the $100,000 award for its project, The GVHD-Focused Telehealth Clinic, which aims to expand access and provide remote specialized GVHD care to new patients within and outside of its traditional providing area to address healthcare disparities that affect medically underserved communities. This project was selected by the independent judging panel given its focus on ensuring GVHD patients and their caregivers from all backgrounds are able to access advanced GVHD providers through a telehealth platform. Pending a successful establishment and scalability of this GVHD telehealth clinic, the judges hope this project will serve as a nationwide model for other organizations to follow and adapt to their regional specific needs.

The Aplastic Anemia and MDS International Foundation has been selected to receive the $35,000 award for its project, the GVHD Interactive Provider Network, which aims to increase access to expert advice and mentoring by connecting GVHD specialists with community-based providers. Through these connections, GVHD specialists will be able to share their expertise and discuss specific cases to improve care outside of major academic centers. This novel project was selected given its goal of tackling concerns of inequitable care that some GVHD patients may face.

“We are pleased that the GVHD community came together again in the second year of this important award program to develop the compelling submissions received from research centers and patient advocacy groups across the nation,” said Barry Flannelly, Pharm. D., Executive Vice President and General Manager, North America, Incyte. “We look forward to supporting the advancement of the selected initiatives from Memorial Sloan Kettering Cancer Center and the Aplastic Anemia and MDS International Foundation over the next year, which aim to address key barriers that may prevent equitable care and support for those with GVHD.”
The independent judging panel included the following GVHD experts and advocates: Gerry Cowden, Founder, Meredith Cowden Foundation; Shrina Duggal, Pharm. D., BCOP, Clinical Pharmacy Specialist, University of Pittsburgh Medical Center Hillman Cancer Center; Navneet Majhail, M.D., Director, Blood and Marrow Transplant Program, Cleveland Clinic; Peggy Burkhard, Executive Director, National Bone Marrow Transplant Link; and Miguel-Angel Perales, M.D., Chief, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center. To uphold the integrity of the judging process, any judge that was affiliated with an applying organization was precluded from the review of that organization’s application.

To read more about these winning initiatives, and for more information about the Incyte Ingenuity Award program, visit [https://www.incyteingenuityawards.com/](https://www.incyteingenuityawards.com/).

**About GVHD**
GVHD is a condition that can occur after an allogeneic stem cell transplant (the transfer of stem cells from a donor), where the donated cells initiate an immune response and attack the transplant recipient’s organs, leading to significant morbidity and mortality. There are two major forms of GVHD: acute, which generally occurs within 100 days of transplant, and chronic, which generally occurs after 100 days of transplant. Both forms can affect multiple organ systems, including the skin, gastrointestinal (digestive) track and liver.

**About Incyte**
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit [Incyte.com](https://www.incyte.com) and follow [@Incyte](https://twitter.com/Incyte).

###

**Contacts:**
Jenifer Antonacci  
Senior Director, Public Affairs  
Tel: +1 302 498 7036  
jantonacci@incyte.com

Kristen Griffiths  
Senior Manager, Public Affairs  
Tel: +1 302 498 7012  
kgriffiths@incyte.com